Rubicon Research (RUBICON) Q3 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 25/26 earnings summary
13 Aug, 2026Executive summary
Unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, were approved by the Board and reviewed by statutory auditors.
The company completed a successful IPO in the quarter, raising ₹13,775 million and listing on NSE and BSE on October 16, 2025.
Financial highlights
Consolidated revenue from operations for Q3 FY26 was ₹4,755.29 million, up from ₹3,133.96 million in Q3 FY25; nine-month revenue was ₹12,400.41 million, up from ₹9,261.25 million year-over-year.
Consolidated net profit after tax for Q3 FY26 was ₹727.97 million, compared to ₹380.73 million in Q3 FY25; nine-month net profit was ₹1,699.50 million, up from ₹981.16 million year-over-year.
Standalone revenue for Q3 FY26 was ₹3,017.11 million, with net profit after tax of ₹371.81 million; nine-month standalone net profit was ₹1,181.45 million.
Basic EPS (consolidated) for Q3 FY26 was ₹4.46, up from ₹2.50 in Q3 FY25; nine-month EPS was ₹10.82, up from ₹6.45 year-over-year.
Research and development expenditure for the nine months was ₹1,379.24 million (consolidated).
Outlook and guidance
The company is focused on utilizing IPO proceeds for debt repayment and strategic growth, with significant unutilized funds earmarked for future acquisitions and initiatives.
Management believes the impact of new Indian Labour Codes has been recognized and accounted for in employee benefits.
Latest events from Rubicon Research
- Q1 FY27 delivered strong revenue and profit growth, with margin guidance raised to 23%.RUBICON
Q1 26/27 - Quarterly net profit of ₹255.65 million on revenue of ₹3,167.19 million, driven by US sales.RUBICON
Q1 25/26 - FY26 saw robust revenue and profit growth, a successful IPO, and a recommended ₹1.50 dividend.RUBICON
Q4 25/26 - Revenue up 50% YoY, net profit at ₹13,436 lakhs, and major US acquisition completed.RUBICON
Q4 24/25 - Strong revenue and profit growth, successful IPO, and strategic biotech investments.RUBICON
Q2 25/26